



Report on Enhancing Peer Review at NIH Implementation Plan

**96th Meeting of the Advisory
Committee to the Director**

**Lawrence A. Tabak, DDS, PhD
June 6th, 2008**



Reviewing and Improving Peer Review at NIH

- Reality: First-rate peer review is a cornerstone of NIH
- Emerging Reality: Increasing breadth, complexity, interdisciplinary nature of biomedical science are creating new challenges for peer review
- Funding trends aggravate the stress on peer review
- NIH Response: Reviewing – and enhancing – peer review

The Continuing Charge:


“Fund the best science, by the best scientists, with the least administrative burden...”

And the Added Challenge:

... but recognize that “best” is dependent on many factors including: scientific quality; public health impact; mission of Institute or Center; existing NIH portfolio



Enhancing Peer Review



Jul 07 - Feb 08

Mar 08 - June 08

June 08

- Request For Information
- 2 Deans Teleconferences
- ACD & SC Working Groups
- 5 Regional Meetings
- National Advisory Councils
- NIH Functional Committees
- Scientific Liaisons
- NIH Staff

- NIH Staff & Public Comment
- SC Peer Review Implementation Groups
- Position Papers from NIH Functional Committees
- SRO/NIH Staff Town Hall Meeting

- Advisory Committee to the Director
- Study Section Chairs
- NIH Functional Committees
- IC Directors
- Steering Committee
- Peer Review Advisory Committee

Draft Recommendations Report

Feb 29, 2008

SC Peer Review Cross Cutting Committee

Input on Draft Recommendations Report


Draft Implementation Plan

Apr 15, 2008



Granularity of the Discussion:

We need to tackle the big challenges



Guided by several principles:

- 1. Do no harm**
- 2. Continue to maximize the freedom of scientists to explore**
- 3. Focus on the changes that are most likely to add significant value at a reasonable cost/benefit ratio**

Four Core Priorities Emerged


- 1. Engage the best reviewers**
- 2. Improve the quality and transparency of reviews**
- 3. Ensure balanced and fair reviews across scientific fields and scientific career stages and reduce burden on applicants**
- 4. Develop a permanent process for continuous review of peer review**



Priority 1: Engage the Best Reviewers

- ***The excellence of peer review is directly correlated to our ability to recruit and retain the most accomplished, broad-thinking and creative scientists to serve on study sections***

Academic Rank of All CSR Reviewers



Priority 1: Engage the Best Reviewers

- **Goal 1: Increase flexibility of service to better accommodate reviewers**
 - **Spread 12 session reviewer commitment over 4-6 years**
 - **Allow duty-sharing by colleagues as appropriate**
 - **Expand use of flexible submission deadlines**
 - **Pilot and evaluate new forms of high bandwidth electronic review**



Priority 1: Engage the Best Reviewers

- **Goal 2: Recruit additional accomplished reviewers to serve on study section**
 - **Enhance recruitment strategies to attract a greater number of accomplished extramural and intramural investigators to serve as reviewers**
 - **Establish a policy that certain classes of NIH grant awards would include a service expectation for PIs, including:**
 - **Honorific awards: Merit/Javits, Pioneer**
 - **Grants where the PI is named as PI on three or more additional R01 equivalents**
 - **Type 2 renewals with >\$500K direct costs**



Priority 1: Engage the Best Reviewers

- **Goal 3: More formally acknowledge the efforts of all reviewers**
- **Goal 4: Make the review experience intellectually more rewarding**
 - **Focus the discussion on impact and innovation/originality of proposals**
 - **Ranking proposals at the meeting's conclusion will provide feedback to the study section members**
 - **Study sections will be engaged directly in the piloting of many of the interventions**



Priority 1: Engage the Best Reviewers

- **Goal 5: Compensate the time and effort required for outstanding and sustained service for those reviewers who serve for a minimum of 18 full study section meetings as chartered members or equivalent service**
 - Individuals may apply for an administrative supplement of up to \$250K (TC)
 - Individuals may request that they be considered for Merit/Javits awards on a competitive basis
- **Goal 6: Enhance review quality by providing additional training and mentoring to all study section chairs, reviewers and Scientific Review Officers**
 - Develop an NIH-wide standardized core curriculum based on best practices augmented by IC and study section-specific additions



Priority 2: Improve the Quality and Transparency of Reviews

- Peer review must consistently identify an application's relative merit, potential for scientific and/or public health impact, and feasibility

- The reliability of individual rating scales is a monotonically increasing function of the number of steps
- As the number of scale steps increases from 2 to 20, the increase in reliability is very rapid at first, but tends to level off at about 7
- A seven scale steps provides appropriate balance between scale reliability and discriminative demand on the respondent

(Nunnally, 1978)

1
1.1
1.2
1.3
1.4
1.5
1.6
1.7
1.8
1.9
2
2.1
2.2
2.3
2.4
2.5
2.6
2.7
2.8
2.9
3
3.1
3.2
3.3
3.4
3.5
3.6
3.7
3.8
3.9
4
4.1
4.2
4.3
4.4
4.5
4.6
4.7
4.8
4.9
5

41 Scale Steps Today

1
2
3
4
5
6
7

7 Scale Steps Tomorrow



Priority 2: Improve the Quality and Transparency of Reviews

- **Goal 1: Modify the rating system to focus on specific review criteria, with less emphasis on methodological details and more emphasis on potential scientific impact**
 - **Assigned reviewers will provide individual scores for each of five review criteria (1→7) and a preliminary global score**
 - **5 specific review criteria: impact, investigator(s), innovation/originality, project plan/feasibility and environment**



Priority 2: Improve the Quality and Transparency of Reviews

- **Goal 1: Modify the rating system to focus on specific review criteria, with less emphasis on methodological details and more emphasis on potential scientific impact (continued)**
 - **For applications that are not streamlined:**
 - **All study section members, based on a discussion of each criterion, will provide a global score (1→7)**
 - **After initial scoring, all proposals within relevant categories will be discussed as a group and ranked in some manner**
 - **Ranking at the conclusion of meeting allows for “recalibration” of global scores**
 - **To provide all applicants with specific feedback, applications that are streamlined will receive five scores - one for each criterion, representing the average from all reviewers**

Priority 2: Improve the Quality and Transparency of Reviews

- **Goal 2: Restructure the summary statement to align with the explicit rating criteria**
 - **Develop and use a summary statement template with a separate field and prescribed amount of space for each criterion**
 - **Provide an optional field for reviewers who wish to provide applicants with additional advice (“mentoring”) including the opinion that the proposal should not be resubmitted unless fundamentally revised as a new application**
 - **Develop appropriate tools, guidance and training for reviewers for best practices for generating summary statements**



Priority 2: Improve the Quality and Transparency of Reviews

- **Goal 3: Shorten and redesign applications to align with the NIH review criteria starting with R01, R15, R21, R03, K, and F applications**
 - **Twelve pages for R01s, with other mechanisms to be scaled appropriately**
 - **Structure of application will align with explicit review criteria**
 - **The use of an appendix of up to 8 pages will be permitted, but only for specific information that is deemed critical on the basis of NIH-defined criteria (e.g., elements for a clinical trial or a large epidemiologic study)**




Priority 3: Ensure Balanced and Fair Reviews Across Scientific Fields and Career Stages

- *Peer review should fairly evaluate proposals from all scientists, regardless of their career stage or discipline, and avoid bias towards more conservative and proven approaches at the expense of innovation and originality*
- It should not disadvantage early stage investigators
- It should apply the appropriate weighting of past performance and future potential for impact as a function of career stage and productivity
- It should be designed to minimize the need for repeated or multiple applications from meritorious scientists to achieve funding support
- It should encourage “transformative” research




Age Distribution of NIH RPG Investigators: 1980




Sources: IMPAC II Current and History Files

Age Distribution of NIH RPG Investigators: 2006




Sources: IMPAC II Current and History Files


Preliminary Projection of Age Distribution of NIH RPG Investigators: 2020



Impact of Budget Growth on Number of New R01 Investigators



Number of Scored Applications from First-time Investigators are Dropping



Priority 3: Ensure Balanced and Fair Reviews Across Scientific Fields and Career Stages

- **Goal 1: Continue to support and develop policies to fund a minimum number of early stage investigators (ESI) and new (to NIH) investigators, as appropriate**
 - **Cluster review, discussion, scoring and ranking of ESI within a study section**
 - **Pilot percentiling ESI across all study sections**
 - **NIH will work to ensure that the number of fully discussed proposals from ESI is not disproportionately reduced**
- **Goal 2: For more experienced investigators, place equal emphasis on a retrospective assessment of accomplishments and a prospective assessment of what is being proposed**
- **Goal 3: Cluster the review, discussion, scoring and ranking of clinical research applications within a study section**



Priority 3: Ensure Balanced and Fair Reviews Across Scientific Fields and Career Stages:

Encouraging “Transformative” Research

○ **Goal 4: Encourage and expand upon the Pioneer, EUREKA and New Innovator awards review experience to encourage risk taking by applicants**

- **Applicants propose ideas with “transformative” potential as main criterion in concert with a prospective evaluation to measure effectiveness of this approach**
- **Continue to grow the Transformative Research portfolio to reach to ~1% of R01-like awards**
 - **Pioneer and New Innovator Award: \geq \$550M over 5 years**
 - **EUREKA Award: \geq \$200M over 5 years**
 - **New, investigator-initiated “transformative” R01 pathway using the NIH Roadmap authority and funding: \geq \$250M over 5 years**




Priority 3: Ensure Balanced and Fair Reviews Across Scientific Fields and Career Stages:

Reducing Burden on Applicants, Reviewers and NIH staff


- **Goal 5: Based on analysis of success rates as a function of initial scores, reduce the need for resubmissions**
 - **Reduce the rate of resubmissions from applicants with high likelihood of funding based on A0 review**
 - **Reduce the rate of resubmissions for applicants with very low or no likelihood of funding based on A0 review**
 - **Establish policies to carefully rebalance success rates among A0, A1 and A2 submissions to increase system efficiency**
 - **Share relevant review and funding data with all applicants (statistics on cumulative success rates as a function of score or percentile will be made part of summary statement)**



Percent R01-equivalent Awards and Amendment Status



Percent of Unsolicited Type 1 R01 Applications Funded




Change in the Number of Unsolicited Type 1 R01 Applications, Awards by Amendment Status

Year of Original (A0) Submission


	1998	1999	2000	2001	2002	2003	2004	2005	2006
Actual A0 Apps	8886	11214	11245	10713	10945	12041	13916	14153	14171
Actual A0 Awards	1631	2083	2064	1853	1827	1714	1574	1225	945
Actual A0 % Paid	18%	19%	18%	17%	17%	14%	11%	9%	7%
Actual A1 Apps	3175	3972	4015	3993	4490	5144	6287	6467	6463
Actual A1 Awards	1058	1218	1291	1260	1409	1449	1525	1462	1400
Actual A1 % Paid	33%	31%	32%	32%	31%	28%	24%	23%	22%
Actual A2 Apps	821	1073	1073	1075	1355	1665	2240	2342	2146
Actual A2 Awards	324	465	506	492	573	638	912	1025	956
Actual A2 % Paid	39%	43%	47%	46%	42%	38%	41%	44%	45%



Improvement in Median A1 to A2 Priority Score



Number of Type 1 R01 Applications Required for Funding



Priority 4: Develop a Permanent Process for Continuous Review of Peer Review


- ***The NIH peer review process should commit itself to a continuous quality control and improvement process based on a more rigorous and independent prospective evaluation that favor rather than discourage adaptive and innovative approaches to review and program management***
- **Pilot and evaluate new models of review**
 - **2 stage reviews (editorial board models)**
 - **The use of “prebuttals”**
- **Pilot and evaluate different methods for ranking relative merit of applications**
- **Pilot and evaluate high bandwidth electronic review**
- **Develop metrics for monitoring performance of review**



Consideration of Salary Support and Percent Effort



Two-thirds of NIH principal investigators have 50% or less in aggregate percent effort



Minimum Percent Effort

- Unintended consequences related to different business models used by applicant organizations
- **Alternative proposal**: Include a subfield in the “Environment” section of the application where applicants must indicate if they have (or project having) NIH RPG support in excess of \$1M (at the time when the current application would be funded)
- In such cases the applicant must justify why additional resources are being requested at this time




Next Steps

- **Ad hoc Peer Review Task Force, chaired by NIH Deputy Director, will be formed to develop detailed plans and oversee initial implementation**
- **New entity to be formed within the Division of Program Coordination, Planning and Strategic Initiatives to oversee Continuous Review of Peer Review**



Reviewing Peer Review: Project Phases



Thank you

- **Jeremy Berg (NIGMS)**
 - **Keith Yamamoto, ACD (UCSF)**
 - **Syed Ahmed COPR, (MCW)**
 - **Bruce Alberts (UCSF)**
 - **Mary Beckerle, ACD (U. Utah)**
 - **David Botstein, ACD (Princeton)**
 - **Helen Hobbs (UTSW, HHMI)**
 - **Erich Jarvis (Duke)**
 - **Alan Leshner, ACD (AAAS)**
 - **Philippa Marrack (Natl. Jewish Med, HHMI)**
 - **Marjorie Mau (U. Hawaii)**
 - **Edward Pugh, PRAC (U. Penn)**
 - **Tadataka Yamada, ACD (Gates)**
 - **Raynard Kington, (OD)**
 - **Story Landis (NINDS)**
 - **Norka Ruiz Bravo (OD)**
 - **Lana Skirboll (OD)**
 - **Toni Scarpa (CSR)**
 - **Jack Jones (CIT)**
 - **Catherine Manzi (OGC)**
 - **Barbara McGarey (OGC)**
 - **Jennifer Spaeth (OD)**
 - **Rod Pettigrew (NIBIB)**
 - **Josie Briggs (NCCAM)**
 - **Louise Ramm (NCRR)**
 - **Marvin Kalt (NIAID)**
 - **Brent Stanfield (NIDDK)**
 - **Jane Steinberg (NIMH)**
 - **Paulette Gray (NCI)**
 - **Joe Ellis (OER)**
 - **Sally Rockey (OER)**
 - **Jim Onken (OER)**
 - **Cheryl Kitt (CSR)**
 - **John Bartrum (OD)**
 - **Faye Austin (NIGMS)**
 - **Stephen Mockrin (NHLBI)**
 - **Don Schneider (CSR)**
 - **Ann Hagan (NIGMS)**
 - **Sally Amero (OER)**
 - **Bob Finkelstein (NINDS)**
 - **Charles Hackett (NIAID)**
 - **Sheryl Brining (NCRR)**
 - **Dinah Singer (NCI)**
 - **Betty Tai (NIDA)**
 - **Alan Willard (NINDS)**
 - **Yan Wang (NIAMS)**
 - **Ramesh Vemuri (NIA)**
 - **Ravi Basavappa (NIGMS)**
 - **Valerie Prenger (NHLBI)**
 - **Suzanne Fisher (CSR)**
 - **Michael Hilton (NIAAA)**
 - **Craig Jordan (NIDCD)**
 - **Glen Nuckolls (NIAMS)**
 - **Sherry Mills (OER)**
 - **Wally Schaffer (OER)**
 - **Cindy Miner (NIDA)**
 - **Marilyn Miller (NIA)**
 - **Anita Sostek (CSR)**
 - **Members of NIH Functional Committees –
EPMC, eRA, GMAC, RPC, PLC, TAC and EAWG**
- SPECIAL THANKS TO:**
- ***Amy Adams (OD)***
 - ***Kerry Brink (OD)***
 - ***Jennifer Weisman (OD/AAAS)***
 - ***Judith Greenberg (NIGMS)***
 - ***Penny Burgoon (OD)***
 - ***Alison Davis (OD/NIGMS)***
 - ***Vesna Kutlesic (OD/AAAS)***
 - ***Stephano Bertuzzi (OD)***

